The pharmaceutical industry is facing a big headwind in 2019, as net price declines become the new normal. With most big pharma manufacturers having now reported fourth quarter financials and provided some financial outlook for 2019, it is clear industry's drug pricing power has been greatly diminished, at least when it comes to price increases on mature marketed medicines, and the result will impact growth.
Overall, drug makers mostly met or exceeded 2018 financial guidance, but big pharma companies made it clear investors should brace...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?